300 related articles for article (PubMed ID: 25263451)
1. Posttranslational modifications of RUNX1 as potential anticancer targets.
Goyama S; Huang G; Kurokawa M; Mulloy JC
Oncogene; 2015 Jul; 34(27):3483-92. PubMed ID: 25263451
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.
Matsumura T; Nakamura-Ishizu A; Muddineni SSNA; Tan DQ; Wang CQ; Tokunaga K; Tirado-Magallanes R; Sian S; Benoukraf T; Okuda T; Asou N; Matsuoka M; Osato M; Suda T
Blood; 2020 Oct; 136(17):1919-1932. PubMed ID: 32573733
[TBL] [Abstract][Full Text] [Related]
3. Post-translational modifications of Runx1 regulate its activity in the cell.
Wang L; Huang G; Zhao X; Hatlen MA; Vu L; Liu F; Nimer SD
Blood Cells Mol Dis; 2009; 43(1):30-4. PubMed ID: 19386523
[TBL] [Abstract][Full Text] [Related]
4. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1.
Li X; Vradii D; Gutierrez S; Lian JB; van Wijnen AJ; Stein JL; Stein GS; Javed A
J Cell Biochem; 2005 Nov; 96(4):795-809. PubMed ID: 16149049
[TBL] [Abstract][Full Text] [Related]
5. The nonreceptor tyrosine kinase c-Abl phosphorylates Runx1 and regulates Runx1-mediated megakaryocyte maturation.
Liu H; Cui Y; Wang GF; Dong Q; Yao Y; Li P; Cao C; Liu X
Biochim Biophys Acta Mol Cell Res; 2018 Aug; 1865(8):1060-1072. PubMed ID: 29730354
[TBL] [Abstract][Full Text] [Related]
6. An intragenic long noncoding RNA interacts epigenetically with the RUNX1 promoter and enhancer chromatin DNA in hematopoietic malignancies.
Wang H; Li W; Guo R; Sun J; Cui J; Wang G; Hoffman AR; Hu JF
Int J Cancer; 2014 Dec; 135(12):2783-94. PubMed ID: 24752773
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
[TBL] [Abstract][Full Text] [Related]
8. Regulation of RUNX1/AML1 during the G2/M transition.
Wang S; Zhang Y; Soosairajah J; Kraft AS
Leuk Res; 2007 Jun; 31(6):839-51. PubMed ID: 17023045
[TBL] [Abstract][Full Text] [Related]
9. [Epigenetic mechanism of RUNX1 in pathogenesis of leukemia].
Zhang H; Zheng HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):525-30. PubMed ID: 20416203
[TBL] [Abstract][Full Text] [Related]
10. The ubiquitin ligase RNF38 promotes RUNX1 ubiquitination and enhances RUNX1-mediated suppression of erythroid transcription program.
Yonezawa T; Takahashi H; Shikata S; Sawasaki T; Kitamura T; Goyama S
Biochem Biophys Res Commun; 2018 Nov; 505(3):905-909. PubMed ID: 30309654
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional Auto-Regulation of RUNX1 P1 Promoter.
Martinez M; Hinojosa M; Trombly D; Morin V; Stein J; Stein G; Javed A; Gutierrez SE
PLoS One; 2016; 11(2):e0149119. PubMed ID: 26901859
[TBL] [Abstract][Full Text] [Related]
12. RUNX1 translocations and fusion genes in malignant hemopathies.
De Braekeleer E; Douet-Guilbert N; Morel F; Le Bris MJ; Férec C; De Braekeleer M
Future Oncol; 2011 Jan; 7(1):77-91. PubMed ID: 21174539
[TBL] [Abstract][Full Text] [Related]
13. Targeting p38 MAP kinase signaling in cancer through post-translational modifications.
Zou X; Blank M
Cancer Lett; 2017 Jan; 384():19-26. PubMed ID: 27725227
[TBL] [Abstract][Full Text] [Related]
14. MiR-18a increased the permeability of BTB via RUNX1 mediated down-regulation of ZO-1, occludin and claudin-5.
Miao YS; Zhao YY; Zhao LN; Wang P; Liu YH; Ma J; Xue YX
Cell Signal; 2015 Jan; 27(1):156-67. PubMed ID: 25452107
[TBL] [Abstract][Full Text] [Related]
15. The E3 ligase DTX2 inhibits RUNX1 function by binding its C terminus and prevents the growth of RUNX1-dependent leukemia cells.
Yonezawa T; Takahashi H; Hao Y; Furukawa C; Tsuchiya A; Zhang W; Fukushima T; Fukuyama T; Sawasaki T; Kitamura T; Goyama S
FEBS J; 2023 Nov; 290(21):5141-5157. PubMed ID: 37500075
[TBL] [Abstract][Full Text] [Related]
16. Regulation of chromatin structure via histone post-translational modification and the link to carcinogenesis.
Thompson LL; Guppy BJ; Sawchuk L; Davie JR; McManus KJ
Cancer Metastasis Rev; 2013 Dec; 32(3-4):363-76. PubMed ID: 23609752
[TBL] [Abstract][Full Text] [Related]
17. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.
Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Urano T; Takahashi S; Homma Y; Aburatani H; Inoue S
Oncotarget; 2015 Feb; 6(4):2263-76. PubMed ID: 25537508
[TBL] [Abstract][Full Text] [Related]
18. The Leukemia Inhibitory Factor Receptor Gene Is a Direct Target of RUNX1.
Qadi AA; Taberlay PC; Phillips JL; Young A; West AC; Brettingham-Moore KH; Dickinson JL; Holloway AF
J Cell Biochem; 2016 Jan; 117(1):49-58. PubMed ID: 26060100
[TBL] [Abstract][Full Text] [Related]
19. [Transcription factor RUNX1].
Markova EN; Petrova NV; Razin SV; Kantidze OL
Mol Biol (Mosk); 2012; 46(6):846-59. PubMed ID: 23350231
[TBL] [Abstract][Full Text] [Related]
20. Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1alpha.
Peng ZG; Zhou MY; Huang Y; Qiu JH; Wang LS; Liao SH; Dong S; Chen GQ
Oncogene; 2008 Jan; 27(6):839-47. PubMed ID: 17684492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
